(WVE) Wave Life Sciences - Ratings and Ratios
RNA Editing, GalNAc-Conjugated siRNA, Exon Skipping, Allele-Selective
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 88.2% |
| Value at Risk 5%th | 118% |
| Relative Tail Risk | -18.48% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.59 |
| Alpha | -4.76 |
| CAGR/Max DD | 0.65 |
| Character TTM | |
|---|---|
| Hurst Exponent | |
| Beta | 1.081 |
| Beta Downside | 2.671 |
| Drawdowns 3y | |
|---|---|
| Max DD | 66.67% |
| Mean DD | 27.75% |
| Median DD | 24.09% |
Description: WVE Wave Life Sciences November 12, 2025
Wave Life Sciences Ltd. (NASDAQ: WVE) is a Singapore-based, clinical-stage biotech that builds RNA-based medicines using its proprietary PRISM platform, which integrates multiple oligonucleotide chemistries, genetic insight, and modality flexibility to target both rare and common diseases.
The current pipeline includes: WVE-006 (RNA-editing for alpha-1 antitrypsin deficiency), WVE-007 (GalNAc-conjugated siRNA aimed at INHBE for obesity), WVE-N531 (exon-skipping for Duchenne muscular dystrophy), and WVE-003 (allele-selective oligonucleotide for Huntington’s disease). The company leverages strategic collaborations with GlaxoSmithKline, Takeda, and Asuragen, which provide milestone-based funding and potential co-commercialization rights. As of the most recent filing (Q3 2024), Wave reported approximately $150 million of cash and marketable securities, giving it roughly 18 months of runway at current burn rates-a key KPI for assessing near-term financing risk. The broader RNA-therapeutics sector is expanding at a compound annual growth rate of ~12 % (2023-2028), driven by advances in delivery technologies and increasing acceptance of nucleic-acid drugs, which underpins the market opportunity for Wave’s platform.
If you’re looking for a data-rich, quantitative assessment of Wave’s valuation and risk profile, a deeper dive into ValueRay’s analyst dossier may be a useful next step.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-121.9m TTM) > 0 and > 6% of Revenue (6% = 6.55m TTM) |
| FCFTA -0.82 (>2.0%) and ΔFCFTA -42.54pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 118.6% (prev 286.9%; Δ -168.2pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.82 (>3.0%) and CFO -197.4m <= Net Income -121.9m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 2.51 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (167.7m) change vs 12m ago 26.54% (target <= -2.0% for YES) |
| Gross Margin 35.83% (prev 83.79%; Δ -47.96pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 36.42% (prev 14.95%; Δ 21.46pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -11.60 (EBITDA TTM -124.7m / Interest Expense TTM -11.5m) >= 6 (WARN >= 3) |
Altman Z'' -17.11
| (A) 0.54 = (Total Current Assets 215.5m - Total Current Liabilities 85.9m) / Total Assets 241.4m |
| (B) -5.27 = Retained Earnings (Balance) -1.27b / Total Assets 241.4m |
| warn (B) unusual magnitude: -5.27 — check mapping/units |
| (C) -0.44 = EBIT TTM -133.4m / Avg Total Assets 299.9m |
| (D) -0.42 = Book Value of Equity -49.5m / Total Liabilities 116.8m |
| Total Rating: -17.11 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.88
| 1. Piotroski 1.0pt |
| 2. FCF Yield -7.11% |
| 3. FCF Margin data missing |
| 4. Debt/Equity 0.16 |
| 5. Debt/Ebitda 1.41 |
| 6. ROIC - WACC (= -92.77)% |
| 7. RoE -75.61% |
| 8. Rev. Trend 30.15% |
| 9. EPS Trend 51.56% |
What is the price of WVE shares?
Over the past week, the price has changed by -9.24%, over one month by -16.68%, over three months by +114.60% and over the past year by +17.97%.
Is WVE a buy, sell or hold?
- Strong Buy: 9
- Buy: 3
- Hold: 1
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the WVE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 31.6 | 104.8% |
| Analysts Target Price | 31.6 | 104.8% |
| ValueRay Target Price | 17.9 | 15.7% |
WVE Fundamental Data Overview January 04, 2026
P/S = 27.1251
P/B = 25.3548
Beta = -1.721
Revenue TTM = 109.2m USD
EBIT TTM = -133.4m USD
EBITDA TTM = -124.7m USD
Long Term Debt = 19.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 8.39m USD (from shortTermDebt, last quarter)
Debt = 19.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -176.4m USD (from netDebt column, last quarter)
Enterprise Value = 2.79b USD (2.96b + Debt 19.8m - CCE 196.2m)
Interest Coverage Ratio = -11.60 (Ebit TTM -133.4m / Interest Expense TTM -11.5m)
FCF Yield = -7.11% (FCF TTM -198.2m / Enterprise Value 2.79b)
FCF Margin = -181.4% (FCF TTM -198.2m / Revenue TTM 109.2m)
Net Margin = -111.6% (Net Income TTM -121.9m / Revenue TTM 109.2m)
Gross Margin = 35.83% ((Revenue TTM 109.2m - Cost of Revenue TTM 70.1m) / Revenue TTM)
Gross Margin QoQ = 100.0% (prev 74.76%)
Tobins Q-Ratio = 11.54 (Enterprise Value 2.79b / Total Assets 241.4m)
Interest Expense / Debt = 14.57% (Interest Expense 2.88m / Debt 19.8m)
Taxrate = -0.0% (0.0 / -53.9m)
NOPAT = -133.4m (EBIT -133.4m * (1 - -0.00%)) [loss with tax shield]
Current Ratio = 2.51 (Total Current Assets 215.5m / Total Current Liabilities 85.9m)
Debt / Equity = 0.16 (Debt 19.8m / totalStockholderEquity, last quarter 124.5m)
Debt / EBITDA = 1.41 (negative EBITDA) (Net Debt -176.4m / EBITDA -124.7m)
Debt / FCF = 0.89 (negative FCF - burning cash) (Net Debt -176.4m / FCF TTM -198.2m)
Total Stockholder Equity = 161.3m (last 4 quarters mean from totalStockholderEquity)
RoA = -50.52% (Net Income -121.9m / Total Assets 241.4m)
RoE = -75.61% (Net Income TTM -121.9m / Total Stockholder Equity 161.3m)
RoCE = -73.71% (EBIT -133.4m / Capital Employed (Equity 161.3m + L.T.Debt 19.8m))
RoIC = -82.74% (negative operating profit) (NOPAT -133.4m / Invested Capital 161.3m)
WACC = 10.03% (E(2.96b)/V(2.98b) * Re(10.0%) + D(19.8m)/V(2.98b) * Rd(14.57%) * (1-Tc(-0.0)))
Discount Rate = 10.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 32.17%
Fair Price DCF = unknown (Cash Flow -198.2m)
EPS Correlation: 51.56 | EPS CAGR: 75.54% | SUE: -0.38 | # QB: 0
Revenue Correlation: 30.15 | Revenue CAGR: 47.64% | SUE: -0.12 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.32 | Chg30d=-0.010 | Revisions Net=-1 | Analysts=8
EPS next Year (2026-12-31): EPS=-1.21 | Chg30d=-0.056 | Revisions Net=-4 | Growth EPS=-2.8% | Growth Revenue=+8.8%
Additional Sources for WVE Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle